Skip to main content
Medical information Clinical review pending

Cytogenetics

Multiple Myeloma Monitoring Panel Test

A comprehensive blood test panel used to monitor patients diagnosed with multiple myeloma, assessing disease progression and response to treatment. Essential for managing this type of blood cancer.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube AND 5 mL (3 mL min.) serum from 1 SST.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test.
Test priceKSh 21,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Multiple Myeloma Monitoring Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Monitoring patients diagnosed with multiple myeloma.
  • ✓Assessing response to multiple myeloma treatment.
  • ✓Detecting potential disease relapse.
  • ✓Evaluating overall disease status in myeloma patients.
  • ✓Guiding treatment decisions for multiple myeloma.
02

In plain language

What this test helps you understand

This test is used to monitor the progression of multiple myeloma and assess the effectiveness of treatment regimens. It provides crucial information for managing the disease and adjusting therapy as needed.
The Multiple Myeloma Monitoring Panel Test is a vital tool for patients diagnosed with multiple myeloma, a cancer affecting plasma cells in the bone marrow. This test helps healthcare providers track the disease's progression and how well treatment is working, allowing for informed adjustments to care plans.

This comprehensive panel measures several key indicators, including blood cell counts, kidney function markers (Urea, Creatinine), calcium levels, protein levels (Albumin, Serum Protein Electrophoresis, Serum Immunotyping, Kappa/Lambda Light Chains Free, Serum Immunoglobulin Profile), and markers of cell turnover and inflammation (Lactate Dehydrogenase, Beta-2 Microglobulin).

Regular monitoring with this panel is crucial for patients undergoing treatment for multiple myeloma. It helps detect changes in the disease status, identify potential relapses early, and guide decisions about ongoing therapy. Discussing the results with your oncologist is essential for understanding their implications for your specific situation.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test.
Sample3 mL (2 mL min.) whole blood in 1 Lavender Top (EDTA) tube AND 5 mL (3 mL min.) serum from 1 SST.
MethodologyThis panel utilizes various laboratory methods including Complete Blood Count (CBC), chemistry assays, electrophoresis, and immunotyping.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test is a monitoring tool for diagnosed multiple myeloma patients. It is not intended for initial diagnosis. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Multiple myeloma is a type of blood cancer that affects plasma cells, a type of white blood cell found in the bone marrow.
Monitoring helps track the disease's progression, assess treatment effectiveness, and detect relapses early, allowing for timely adjustments to care.
The panel measures various blood components including blood counts, kidney function, calcium, protein levels, and specific myeloma markers like Beta-2 Microglobulin and free light chains.
The frequency of testing depends on your individual situation and treatment plan. Please consult your oncologist for guidance.
Your results will be provided to your referring physician, who will discuss them with you. Confirm with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp